FCER1A and asthma: We elected to focus on asthma as an archetypal disease involving IgE-mediated mechanisms, in which exogenous IgG anti-IgE (omalizumab) has a proven therapeutic role at least in some individuals, and on anti-IgE rather than anti-FcεRI autoantibodies, for the same reason.